# Project: Predicting Phenoconversion

> **NIH NIH U19** · WASHINGTON UNIVERSITY · 2021 · $175,167

## Abstract

ABSTRACT: NAPS2 PROJECT – PREDICTING PHENOCONVERSION
 Rapid eye movement (REM) sleep behavior disorder RBD is a condition in which the muscular paralysis
that accompanies REM sleep is lost, resulting in recurrent dream enactment behavior. RBD occurs in
approximately 40% of patients with PD, 75% of DLB, and 80% of MSA. Idiopathic/Isolated RBD (i.e. without a
known associated neurodegenerative disease) occurs in 1% of the population over 50. Landmark studies have
suggested that >80% of individuals with this form of RBD in fact have prodromal synucleinopathy, and 6-10%
will phenoconvert to PD, DLB, or MSA each year. RBD therefore represents an unprecedented opportunity to
directly study early stages of PD, DLB and MSA in detail. Recognizing the importance of early intervention, the
key federal agencies focused on neurodegenerative disease in the US have proposed high priority
recommendations to study the preclinical and prodromal aspects of synucleinopathies to prepare for clinical
trials. The North American Prodromal Synucleinopathy Consortium, Stage 2 (NAPS2) represents
expanded and extended efforts of the original NAPS Consortium focused on RBD which began in 2018. In
NAPS2, over 300 participants with RBD along with a subset of matched controls will be evaluated in a
comprehensive and standardized manner, with the RBD participants undergoing longitudinal clinical, blood and
CSF, polysomnographic, and neuroimaging studies. These data, samples and scans will be collected,
processed and analyzed in the Cores to provide key variables for conducting hypothesis-driven analyses in the
Project, with the focus on Predicting Phenoconversion. This project will therefore seek to address many
critical scientific issues pertaining to RBD and neuroprotective clinical trial planning, including the following: 1)
determining the degree and distribution of abnormalities in clinical measures, PSG and biofluid biomarkers
among a large cohort of persons with RBD; 2) determining the conversion rate from RBD to an overt
synucleinopathy, and to define predictive biomarkers of phenoconversion; 3) tracking change on clinical
measures and biomarkers to develop progression biomarkers of synucleinopathy, and 4) combining data on
phenoconversion, predictive biomarkers, and progression biomarkers to estimate sample size according to
different patient selection criteria and primary outcomes for neuroprotective clinical trials in RBD.

## Key facts

- **NIH application ID:** 10187091
- **Project number:** 1U19AG071754-01
- **Recipient organization:** WASHINGTON UNIVERSITY
- **Principal Investigator:** Ronald Postuma
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $175,167
- **Award type:** 1
- **Project period:** 2021-08-01 → 2026-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10187091

## Citation

> US National Institutes of Health, RePORTER application 10187091, Project: Predicting Phenoconversion (1U19AG071754-01). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10187091. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*